CBS 2019
CBSMD教育中心
English

Acute Coronary Syndrom

科研文章

荐读文献

Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia Chronic total occlusion intervention of the non-infarct-related artery in acute myocardial infarction patients: the Korean multicenter chronic total occlusion registry Restenosis, Stent Thrombosis, and Bleeding Complications - Navigating Between Scylla and Charybdis Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction BMI, Infarct Size, and Clinical Outcomes Following Primary PCI Patient-Level Analysis From 6 Randomized Trials Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study
|<<... 13 14 15 16 17 18 19 ...>>|

Clinical Trial2018 Jun;200:17-23.

JOURNAL：Am J Cardiol. Article Link

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial

Lopes RD, Vora AN, Liaw D et al. Keywords: apixaban; vitamin K antagonist; aspirin; placebo; ACS; PCI;

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top